Phase I clinical trial - Pédiatrie Tumeurs solides

LYNPARZA (D0816C000025)
Pédiatrie Tumeurs solides
Ouvert depuis le: 09.19.2021
Site: Paris
Public cible
Enfant
A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety;and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with;Solid Tumours
Description de l'essai

Polyadenosine 5Àdiphosphoribose;[poly (ADP ribose)] polymerisation (PARP) inhibition in adults who have platinum sensitive;relapsed epithelial ovarian cancer with and without homologous recombination deficiencies;(HRD) and in locally advanced or metastatic recurrent breast cancer harbouring deleterious or;suspected deleterious mutations of the breast cancer susceptibility genes (BRCA; BRCA1 and;BRCA2) has been identified as an effective treatment approach. PARP inhibition in paediatric;patients with non-central nervous system (CNS) solid tumours that harbour mutations in genes;involved in homologous recombination repair (HRR) may offer a novel alternative treatment;approach.